Drug Profile

Research programme: T cell engager immunotherapies - Janux Therapeutics/ Merck & Co

Latest Information Update: 10 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janux Therapeutics
Class Antineoplastics; Fab fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Feb 2026 Preclinical trials in Cancer in USA (Parenteral) (Janux Therapeutics pipeline, February 2026)
28 Jan 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
18 Dec 2020 T cell engager immunotherapy licensed to Merck & Co Worldwide

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com